CIK in Treating Patients With Esophageal Cancer

ConditionEsophageal Squamous Cell Carcinoma

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-80

SponsorThe First People's Hospital of Changzhou

About this trial

Chemotherapy is the main treatment method for patients with Esophageal Cancer. However, Relapse remains the major cause of treatment failure.Biological therapies such as CIK stimulate the immune system and stop tumor cells from growing. A series of studies reported that cytokine-induced killer cells (CIK) have a broad anti-tumor spectrum. The investigators suppose that CIK will improve the prognosis. Combining chemotherapy with biological therapy may kill more tumor cells. In this study, the patients will be treated with CIK cells after chemotherapy. The purpose of this study is to evaluate the efficacy of CIK for Esophageal Cancer.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients histologically confirmed esophageal carcinoma;

Patients with staging I-III of esophageal carcinoma;

Patients who had completed chemotherapy;

Patients who have a life expectancy of at least 12 weeks;

Disqualifiers

Patients who had distant metastases by imaging studies;

Patients with uncontrolled infection; underlying disease that was severe or life-threatening;

Patients who were lactating;

ECOG perform status ≥ 2;

Trial design

Design model

Parallel

Treatments tested in this trial

Cytokine-induced Killer Cells
Biological/Vaccine
chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment

Treatment groups

2,000 Participants

are divided into 2 treatment groups

Group A: No-CIKNo intervention 0 interventions

Group B: CIKExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

progression-free survival(PFS)

Time frame

1 month

Secondary outcomes

overall survival(OS)

Time frame

1 month

Other outcomes

Stage at diagnosis

Tumor Node Metastasis (TNM) stage, Tumor:CIS,T1,T2,T3,T4 according to the depth of tumor invasion. Lymph node involvement: N0,N1,N2. Metastasis: M0,M1

Time frame

1 month

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The First People's Hospital of Changzhou

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: